Lys85

Site Information
RDHCVAHkLFNNLK_ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461153
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 )
Disease tissue studied:	colorectal cancer ( 14 , 15 ) , colorectal carcinoma ( 14 , 15 ) , gastric cancer ( 10 ) , liver cancer ( 51 ) , hepatocellular carcinoma ( 51 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 2 , 4 , 5 , 6 , 9 , 11 , 12 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 5 ) , non-small cell squamous cell lung carcinoma ( 12 ) , small-cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 1 , 4 , 16 ) , Cal-12T (pulmonary) ( 2 ) , Calu-3 (pulmonary) ( 6 ) , DMS79 (pulmonary) ( 3 ) , HCC44 (pulmonary) ( 2 ) , HCC827 (pulmonary) ( 6 ) , HCT116 (intestinal) ( 14 , 15 , 40 , 41 , 43 , 44 , 49 , 50 ) , HCT15 (intestinal) ( 45 , 46 ) , HCT8/S11 (intestinal) ( 47 , 48 ) , HeLa (cervical) ( 7 ) , HepG2 (hepatic) ( 51 ) , Jurkat (T lymphocyte) ( 8 , 16 ) , KMS-18 (B lymphocyte) ( 19 ) , lung ( 2 , 3 , 4 , 5 , 6 ) , MKN-45 (gastric) ( 10 ) , MV4-11 (macrophage) ( 31 , 32 , 37 , 38 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1355 (pulmonary) ( 4 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 2 ) , NCI-H1650 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 12 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1792 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H1975 (pulmonary) ( 6 ) , NCI-H209 (pulmonary) ( 3 ) , NCI-H2106 (pulmonary) ( 6 ) , NCI-H23 (pulmonary) ( 4 ) , NCI-H2405 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 9 ) , NCI-H3255 (pulmonary) ( 11 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H524 (pulmonary) ( 3 ) , OCI-ly3 (B lymphocyte) ( 25 , 26 , 27 , 29 , 30 ) , RC-K8 (B lymphocyte) ( 28 ) , Reh (B lymphocyte) ( 20 , 21 ) , SEM (B lymphocyte) ( 22 , 23 , 24 ) , SW620 (intestinal) ( 36 , 42 )

References
1	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
2	Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
11	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
14	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
15	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
17	Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
18	Cherry J (2007) CST Curation Set: 2731; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
19	Cherry J (2007) CST Curation Set: 2729; Year: 2007; Biosample/Treatment: cell line, KMS-18/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
20	Cherry J (2007) CST Curation Set: 2707; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Cherry J (2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
22	Cherry J (2007) CST Curation Set: 2710; Year: 2007; Biosample/Treatment: cell line, SEM/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
23	Cherry J (2007) CST Curation Set: 2711; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
24	Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
25	Cherry J (2007) CST Curation Set: 2513; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
26	Cherry J (2007) CST Curation Set: 2514; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
27	Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
28	Cherry J (2007) CST Curation Set: 2439; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
29	Cherry J (2007) CST Curation Set: 2440; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
30	Cherry J (2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
31	Cherry J (2007) CST Curation Set: 2313; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
32	Cherry J (2007) CST Curation Set: 2314; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
33	Cherry J (2007) CST Curation Set: 2315; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
34	Cherry J (2007) CST Curation Set: 2316; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
35	Cherry J (2007) CST Curation Set: 2317; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
36	Li Y (2006) CST Curation Set: 2115; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
37	Cherry J (2006) CST Curation Set: 2029; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
38	Cherry J (2006) CST Curation Set: 2030; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
39	Cherry J (2006) CST Curation Set: 2033; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
40	Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
41	Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'\|\|' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
42	Li Y (2006) CST Curation Set: 1828; Year: 2006; Biosample1/Treatment/Isotope: cell line, SW620/serum starved &'\|\|' serum starved/L, Biosample2/Treatment/Isotope: cell line, SW620/serum starved/TSA/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
43	Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'\|\|' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
44	Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
45	Li Y (2006) CST Curation Set: 1469; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
46	Li Y (2006) CST Curation Set: 1472; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
47	Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
48	Li Y (2006) CST Curation Set: 1476; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
49	Li Y (2005) CST Curation Set: 966; Year: 2005; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
50	Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
51	Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info